Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy - PubMed (original) (raw)

Randomized Controlled Trial

Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy

David H Henry et al. Oncologist. 2007 Feb.

Free article

Abstract

Purpose: To evaluate the safety and efficacy of intravenous (IV) sodium ferric gluconate complex (FG), oral ferrous sulfate, or no iron to increase hemoglobin (Hb) in anemic cancer patients receiving chemotherapy and epoetin alfa.

Patients and methods: In this open-label, multicenter trial, 187 patients with chemotherapy-related anemia (Hb <11 g/dl; serum ferritin > or =100 ng/ml or transferrin saturation > or =15%) scheduled to receive chemotherapy and epoetin alfa (40,000 U subcutaneously weekly) were randomized to 8 weeks of 125 mg of IV FG weekly, 325 mg of oral ferrous sulfate three times daily, or no iron. The primary outcome was a change in Hb from baseline to endpoint, first whole-blood or red blood cell transfusion, or study withdrawal.

Results: One hundred twenty-nine patients were evaluable for efficacy (FG, n = 41; oral iron, n = 44; no iron, n = 44). Mean increase in Hb was 2.4 g/dl (95% confidence interval [CI], 2.1-2.7) for FG (p = .0092 vs. oral iron; p = .0044 vs. no iron), 1.6 g/dl (95% CI, 1.1-2.1) for oral iron (p =.7695 vs. no iron), and 1.5 g/dl (95% CI, 1.1-1.9) for no iron. Hb response (increase > or =2 g/dl) was 73% for FG (p = .0099 vs. oral iron; p = .0029 vs. no iron), 46% for oral iron (p = .6687 vs. no iron), and 41% for no iron. FG was well tolerated.

Conclusion: For cancer patients with chemotherapy-related anemia receiving epoetin alfa, FG produces a significantly greater increase in Hb and Hb response compared with oral iron or no iron, supporting more aggressive treatment with IV iron supplementation for these patients.

PubMed Disclaimer

Cited by

Inside ANEMIA of CKD: Projecting the Future Burden of Anemia of Chronic Kidney Disease and Benefits of Proactive Management: A Microsimulation Model of the Chinese Population.
Retat L, Xiao D, Webber L, Martin A, Card-Gowers J, Yao J, Zhang Y, Zhang C, Garcia Sanchez JJ, Cabrera C, Grandy S, Rao N, Wu Y, Li Z, Xuan J. Retat L, et al. Adv Ther. 2024 Oct;41(10):3905-3921. doi: 10.1007/s12325-024-02863-4. Epub 2024 Aug 20. Adv Ther. 2024. PMID: 39162981 Free PMC article.
Intravenous Iron Therapy to Treat Anemia in Oncology: A Mapping Review of Randomized Controlled Trials.
Lim J, Auerbach M, MacLean B, Al-Sharea A, Richards T. Lim J, et al. Curr Oncol. 2023 Aug 24;30(9):7836-7851. doi: 10.3390/curroncol30090569. Curr Oncol. 2023. PMID: 37754484 Free PMC article. Review.
Evolution of molecular switches for regulation of transgene expression by clinically licensed gluconate.
Teixeira AP, Xue S, Huang J, Fussenegger M. Teixeira AP, et al. Nucleic Acids Res. 2023 Aug 25;51(15):e85. doi: 10.1093/nar/gkad600. Nucleic Acids Res. 2023. PMID: 37497781 Free PMC article.
Synergistic immunotherapy targeting cancer-associated anemia: prospects of a combination strategy.
Yuan T, Jia Q, Zhu B, Chen D, Long H. Yuan T, et al. Cell Commun Signal. 2023 May 19;21(1):117. doi: 10.1186/s12964-023-01145-w. Cell Commun Signal. 2023. PMID: 37208766 Free PMC article. Review.
Intravenous Iron-Carbohydrate Nanoparticles and Their Similars. What Do We Choose?
Mehedinti AM, Capusa C, Andreiana I, Mircescu G. Mehedinti AM, et al. Maedica (Bucur). 2022 Jun;17(2):436-448. doi: 10.26574/maedica.2022.17.2.436. Maedica (Bucur). 2022. PMID: 36032600 Free PMC article.

Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy - PubMed (original) (raw)